Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Blueprint Medicines Corporation (NASDAQ: BPMC).

Full DD Report for BPMC

You must become a subscriber to view this report.


Recent News from (NASDAQ: BPMC)

Blueprint Medicines to Present at 16th Annual Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass. , Sept. 5, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that company management will participate in a fi...
Source: PR Newswire
Date: September, 05 2018 08:00
Money flow stays positive in biotechs, XBI up 6% since last week
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped  6%  since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
Source: SeekingAlpha
Date: August, 27 2018 11:39
Loxo Oncology: Out Of The Frying Pan And Into The Fire (Part 2/2)
In my previous article on Loxo Oncology ( LOXO ), I introduced the challenges facing LOXO as they transition to becoming a commercial-stage biotech company. In that article, I discuss their R&D strategy, scientific platform, and upcoming clinical and regulatory milestones. In this art...
Source: SeekingAlpha
Date: August, 17 2018 15:54
Loxo Oncology: Out Of The Frying Pan And Into The Fire, Part 1
Loxo Oncology ( LOXO ) is a clinical-stage biopharmaceutical company developing precision, small molecule inhibitors to treat cancer. On May 29, 2018, the FDA accepted the New Drug Application ((NDA)) for Larotrectinib for the treatment of adult and pediatric patients with locally advanced or ...
Source: SeekingAlpha
Date: August, 14 2018 10:54
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2018 Results - Earnings Call Transcript
Start Time: 08:30 End Time: 09:19 Blueprint Medicines Corporation (BPMC) Q2 2018 Earnings Conference Call August 01, 2018, 08:30 AM ET Executives Jeff Albers - CEO Andy Boral - Chief Medical Officer Mike Landsittel - VP of Finance Marion Dorsch - Chief Scientific Officer ...
Source: SeekingAlpha
Date: August, 01 2018 14:58
Blueprint Medicines 2018 Q2 - Results - Earnings Call Slides
The following slide deck was published by Blueprint Medicines in conjunction with their 2018 Q2 earnings Read more ...
Source: SeekingAlpha
Date: August, 01 2018 08:55
Blueprint Medicines  beats by $0.70, beats on revenue
Blueprint Medicines  (NASDAQ: BPMC ): Q2 EPS of -$0.62 beats by $0.70 . More news on: Blueprint Medicines, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 01 2018 07:06
Blueprint Medicines Reports Second Quarter 2018 Financial Results
CAMBRIDGE, Mass. , Aug. 1, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for th...
Source: PR Newswire
Date: August, 01 2018 07:00
Roche's Bet On Allakos Is Too Expensive
Exploring treatments for various eosinophil and mast cell-related diseases, which a few competitors are investigating, Allakos (ALLK) seems to have excited the market. The fact that Roche Holding (RHHBF) has invested in the company will hold the attention of many investors. With that, the shar...
Source: SeekingAlpha
Date: July, 31 2018 20:44
Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
CAMBRIDGE, Mass. , July 25, 2018 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:...
Source: PR Newswire
Date: July, 25 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1057.4459.2259.5656.1295232,037
2018-12-0757.9657.4759.7056.64314,908
2018-12-0657.9458.2959.50556.39493,267
2018-12-0460.3058.4362.5058.27527,267
2018-12-0358.6760.2960.8658.65341,856

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1037,88152,27372.4676Short
2018-12-0759,16967,56687.5722Short
2018-12-0690,214115,45078.1412Short
2018-12-04103,235142,05572.6726Short
2018-12-0371,56095,11675.2345Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on BPMC.


About Blueprint Medicines Corporation (NASDAQ: BPMC)

Logo for Blueprint Medicines Corporation (NASDAQ: BPMC)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $3,549,509,177 - 05/14/2018
  • Issue and Outstanding: 43,837,337 - 04/30/2018

 


Recent Filings from (NASDAQ: BPMC)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 02 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 21 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 21 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: February, 14 2018

 

 


Daily Technical Chart for (NASDAQ: BPMC)

Daily Technical Chart for (NASDAQ: BPMC)


Stay tuned for daily updates and more on (NASDAQ: BPMC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: BPMC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BPMC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of BPMC and does not buy, sell, or trade any shares of BPMC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/